Settlement Structure: Claims Made
Active: Closed
Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions.
Case Summary:A group of entities—including Mylan NV, Mylan Specialty LP, Mylan Pharmaceuticals, Inc., Viatris, Inc., and Heather Bresch—has agreed to pay $246 million to settle class actions alleging that they violated antitrust, federal racketeering, and other laws, preventing effective competition and causing consumers and insurers to pay too much for EpiPen products. The products at issue included the EpiPen Auto-Injector, the EpiPen Jr. Auto-Injector, and any authorized generic versions of these products.
A group of Pfizer companies reached a settlement in this case at a previous date.
Docket Number:2:17-md-02785-DDC-TJJ, MDL No. 2785
Company: Mylan NV
Filing Deadline: July 25, 2022
Class Period: August 24, 2011 to November 1, 2020
Objection Deadline: June 8, 2022
Final Approval Hearing: July 6, 2022
Proof of Purchase:You do not have to submit documentation at this time, but the Settlement Administrator may ask for it later on. If you submitted a Claim Form in 2021 at the time of the settlement with the Pfizer defendants, you do not need to submit another form now.
Eligibility:You may be eligible if you are a member of either of these groups:
- All persons and entities in the US who paid or provided reimbursement for some or all of the price of branded or authorized generic EpiPens, for consumption and not for resale, by themselves, their family members, insureds, plan participants, employees, or beneficiaries, at any time between August 24, 2011 and November 1, 2020; and
- All persons and entities in the Antitrust States who paid or provided reimbursement for some or all of the price of Branded EpiPens, at any time between January 28, 2013 and November 1, 2020, for the purpose of consumption and not resale, by themselves, their family members, insureds, plan participants, employees, or beneficiaries.
The Antitrust States are Alabama, California, Florida, Hawaii, Illinois, Kansas, Maine, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New York, North Carolina, Tennessee, and Utah.
Typical Settlement Amount:The net settlement fund will be divided into two pools, one for individual consumers (20%) and one for third-party payors (80%). The funds will be distributed according to a proposed plan of allocation and distribution.
Total Settlement Amount: $264,000,000
Class Representative Proposed Incentive Fee:Unknown
Law Firms:
Burns Charest LLP
Pritzker Levine LLP
Robbins Geller Rudman & Dowd
Claim Form: Mylan Antitrust EpiPen Settlement Claim Form
Case Name: In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices, and Antitrust Litigation
Settlement Website: Mylan Antitrust EpiPen Settlement Website
Claims Administrator:
AB Data, Ltd.
EpiPen Settlement
c/o A.B. Data, Ltd.
P.O. Box 173113
Milwaukee, WI 53217
info@EpiPenClassAction.com
877-221-7632